Banhbao TV

Vietnam urges MSD to accelerate vaccine manufacturing technology transfer

Vietnamese Deputy Prime Minister Pham Thi Thanh Tra urged MSD to accelerate HPV vaccine technology transfer to VNVC and consider investing in a pharmaceutical and vaccine manufacturing plant in Vietnam.

Vietnamese Deputy Prime Minister Pham Thi Thanh Tra meets MSD representatives in Hanoi
VNA

Vietnamese Deputy Prime Minister Pham Thi Thanh Tra called on pharmaceutical group MSD (Merck Sharp & Dohme) to consider investing in a pharmaceutical and vaccine manufacturing plant in Vietnam.

On the afternoon of November 18, Deputy Prime Minister Pham Thi Thanh Tra received Marc Gailhardou, President of MSD's Intercontinental Region, and a senior delegation from the company in Hanoi, during MSD's 30th anniversary of operations in Vietnam.

At the meeting, the Deputy Prime Minister said the Government would create favourable conditions for MSD's investment and cooperation projects. She called on the group to regard Vietnam as a stable and reliable strategic partner, move ahead with plans to invest in a pharmaceutical and vaccine manufacturing plant, and accelerate the transfer of HPV vaccine technology to Vietnam Vaccine Joint Stock Company (VNVC).

Gailhardou said Vietnam was among MSD's 10 largest markets in the region.

In 2025, MSD supplied medicines and vaccines to more than 400 million people worldwide, including 2.3 million in Vietnam. He spoke highly of Vietnam's focus on disease prevention, reflected in the Law on Disease Prevention and the inclusion of four vaccines, including the HPV vaccine, in the National Expanded Programme on Immunisation through 2030.

Earlier that morning, MSD and VNVC announced a cooperation plan on technology transfer, manufacturing and localisation of strategically important vaccines, contributing to vaccine security and Vietnam's self-reliance.

Tra acknowledged MSD's contributions over the past 30 years. She noted that the group had introduced around 20 advanced medicines and vaccines to Vietnam and pioneered the introduction of Keytruda cancer immunotherapy for Vietnamese patients. The drug now has 28 approved indications across 14 tumour types.

MSD has supported around 7,500 cancer patients, providing medicines worth approximately 4 trillion VND (155.41 million USD) and covering up to 75% of treatment costs. It has also invested trillions of VND in clinical research and pledged an additional 40 million USD in 2026. The group has further provided HPV vaccines at preferential prices through the United Nations-backed Gavi vaccine alliance mechanism until the end of 2027.

The Deputy Prime Minister said Vietnam was now enjoying an unprecedentedly favourable policy and institutional environment. Politburo Resolution No. 72-NQ/TW dated September 9, 2025, on breakthrough solutions to strengthen public health protection, care and improvement, shifts the focus towards preventive healthcare, with the goal of providing people with basic free medical services within their health insurance coverage by 2030, following an appropriate roadmap.

The Pharmaceutical Industry Development Strategy through 2030 aims to make Vietnam a high-value pharmaceutical manufacturing hub in ASEAN, with the domestic market projected to reach approximately 10 billion USD in 2026 and grow by an average of 8-10% annually. The HPV vaccine was officially included in the National Expanded Programme on Immunisation on July 1, 2026.

Regarding the transfer of HPV vaccine technology between MSD and VNVC, the Deputy Prime Minister welcomed the cooperation and expressed the Government's expectation that technology transfer would extend beyond manufacturing and packaging to include pharmaceutical technologies and next-generation technologies, in full compliance with Vietnamese law.

She called for a review of treatment outcomes and health economic effectiveness to update the list of medicines covered by health insurance, ensuring transparency and maintaining the financial balance of the Health Insurance Fund. The Deputy Prime Minister also said the Government would undertake a comprehensive revision of the Law on Pharmacy to establish a more enabling regulatory framework.

The Deputy Prime Minister urged MSD to consider investing in a pharmaceutical and vaccine manufacturing plant in Vietnam.

She also proposed that MSD act as a focal point to help Vietnam negotiate directly with pharmaceutical groups, reducing intermediaries to ensure reasonable and transparent pricing.

Sources: VietnamPlus / Vietnam News Agency